ABOUT THIS EVENT

Beyond Air, Inc. (Nasdaq: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) to treat patients with pulmonary disease and lung infections, visited the Nasdaq MarketSite in Times Square.

NO is involved in several functions in the human body including vasodilation, neurotransmission, and immune response. Beyond Air’s proprietary and patented NO Generator and Delivery System, named LungFit™, produces NO gas from room air, eliminating the need for expensive and cumbersome NO cylinders, the standard method of storing and providing gas for delivery today. Beyond Air’s first 3 indications have global sales potential of >$4 billion. Launch is expected late in 2020 in the United States for the first indication (persistent pulmonary hypertension of the neonate or PPHN) with approval in other countries to follow.  Launch for the second indication in the United States is anticipated in the second half of 2022.

In honor of the occasion, Steve Lisi, CEO & Chairman of the Board, rang the Closing Bell.